Clinical Trials
9 trialsNCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02922543 2022-06-14
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
Completed
NCT00513656 2018-10-23
A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain
Mundipharma Research GmbH & Co KG
Phase 2 Completed
NCT00101998 2017-08-30
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT00241722 2017-08-30
Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Completed
NCT00135577 2015-09-02
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT00256932 2015-09-02
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Completed
NCT00259922 2015-09-02
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Completed
NCT00984334 2013-12-27
Naloxone SR Capsules in Patients With Opioid Induced Constipation
S.L.A. Pharma AG
Phase 2 Completed